{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:54:18Z","timestamp":1772049258686,"version":"3.50.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,21]]},"DOI":"10.7759\/cureus.67432","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:05:53Z","timestamp":1724292353000},"source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic Modalities in Heart Failure: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Tanisha","family":".","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaithanya","family":"Amudha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Raake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulakshna","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab M Din","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karabo K","family":"Marole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra","family":"Maryam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1977.03630170075017","article-title":"Heart failure: a proposed definition and classification","volume":"137","author":"Wagner S","year":"1977","unstructured":"Wagner S, Cohn K. Heart failure: a proposed definition and classification. Arch Intern Med. 1977, 137:675-8. 10.1001\/archinte.1977.03630170075017","journal-title":"Arch Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:e240-327. 10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016, 18:891-975. 10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version","volume":"83","author":"Tsutsui H","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, et al.. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version. Circ J. 2019, 83:2084-184. 10.1253\/circj.CJ-19-0342","journal-title":"Circ J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107 PM","year":"2021","unstructured":"Seferovi\u0107 PM, Vardas P, Jankowska EA, et al.. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail. 2021, 23:906-14. 10.1002\/ejhf.2143","journal-title":"Eur J Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx628","article-title":"European Society of Cardiology: cardiovascular disease statistics 2017","volume":"39","author":"Timmis A","year":"2018","unstructured":"Timmis A, Townsend N, Gale C, et al.. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J. 2018, 39:508-79. 10.1093\/eurheartj\/ehx628","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003866","article-title":"Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey","volume":"4","author":"Hancock HC","year":"2014","unstructured":"Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014, 4:e003866. 10.1136\/bmjopen-2013-003866","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4271-2","article-title":"General practitioners' perceptions about their role in current and future heart failure care: an exploratory qualitative study","volume":"19","author":"Smeets M","year":"2019","unstructured":"Smeets M, Zervas S, Leben H, et al.. General practitioners' perceptions about their role in current and future heart failure care: an exploratory qualitative study. BMC Health Serv Res. 2019, 19:432. 10.1186\/s12913-019-4271-2","journal-title":"BMC Health Serv Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2008","article-title":"Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Jaarsma T","year":"2021","unstructured":"Jaarsma T, Hill L, Bayes-Genis A, et al.. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021, 23:157-74. 10.1002\/ejhf.2008","journal-title":"Eur J Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217889","article-title":"The molecular mechanisms of iron metabolism and its role in cardiac dysfunction and cardioprotection","volume":"21","author":"Ravingerov\u00e1 T","year":"2020","unstructured":"Ravingerov\u00e1 T, Kindernay L, Bartekov\u00e1 M, et al.. The molecular mechanisms of iron metabolism and its role in cardiac dysfunction and cardioprotection. Int J Mol Sci. 2020, 21:7889. 10.3390\/ijms21217889","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1113\/EP091309","article-title":"Effect of exercise on improving myocardial mitochondrial function in decreasing diabetic cardiomyopathy","volume":"109","author":"Zhang F","year":"2024","unstructured":"Zhang F, Lin JJ, Tian HN, Wang J. Effect of exercise on improving myocardial mitochondrial function in decreasing diabetic cardiomyopathy. Exp Physiol. 2024, 109:190-201. 10.1113\/EP091309","journal-title":"Exp Physiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.584800","article-title":"Mitochondrial dynamics in adult cardiomyocytes and heart diseases","volume":"8","author":"Li A","year":"2020","unstructured":"Li A, Gao M, Jiang W, Qin Y, Gong G. Mitochondrial dynamics in adult cardiomyocytes and heart diseases. Front Cell Dev Biol. 2020, 8:584800. 10.3389\/fcell.2020.584800","journal-title":"Front Cell Dev Biol"},{"key":"ref15","article-title":"Physiology, Cardiac Cycle","author":"Pollock JD","year":"2024","unstructured":"Pollock JD, Makaryus AN. Physiology, Cardiac Cycle. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109866","article-title":"Adiponectin enhances the bioenergetics of cardiac myocytes via an AMPK- and succinate dehydrogenase-dependent mechanism","volume":"78","author":"Jeon YH","year":"2021","unstructured":"Jeon YH, He M, Austin J, Shin H, Pfleger J, Abdellatif M. Adiponectin enhances the bioenergetics of cardiac myocytes via an AMPK- and succinate dehydrogenase-dependent mechanism. Cell Signal. 2021, 78:109866. 10.1016\/j.cellsig.2020.109866","journal-title":"Cell Signal"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165649","article-title":"Genome-wide translational reprogramming of genes important for myocyte functions in overload-induced heart failure","volume":"1866","author":"Guo Q","year":"2020","unstructured":"Guo Q, Zhang Y, Zhang S, et al.. Genome-wide translational reprogramming of genes important for myocyte functions in overload-induced heart failure. Biochim Biophys Acta Mol Basis Dis. 2020, 1866:165649. 10.1016\/j.bbadis.2019.165649","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab246","article-title":"Functional and structural adaptations of the coronary macro- and microvasculature to regular aerobic exercise by activation of physiological, cellular, and molecular mechanisms: ESC Working Group on Coronary Pathophysiology and Microcirculation position paper","volume":"118","author":"Koller A","year":"2022","unstructured":"Koller A, Laughlin MH, Cenko E, et al.. Functional and structural adaptations of the coronary macro- and microvasculature to regular aerobic exercise by activation of physiological, cellular, and molecular mechanisms: ESC Working Group on Coronary Pathophysiology and Microcirculation position paper. Cardiovasc Res. 2022, 118:357-71. 10.1093\/cvr\/cvab246","journal-title":"Cardiovasc Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/2050312120965752","article-title":"Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer","volume":"8","author":"Amin MN","year":"2020","unstructured":"Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, Sultana F. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med. 2020, 8:10.1177\/2050312120965752","journal-title":"SAGE Open Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20160005","article-title":"Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment","volume":"106","author":"Azevedo PS","year":"2016","unstructured":"Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol. 2016, 106:62-9. 10.5935\/abc.20160005","journal-title":"Arq Bras Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese NR","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, et al.. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023, 118:3536-55. 10.1093\/cvr\/cvac133","journal-title":"Cardiovasc Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.08.009","article-title":"Iron and heart failure: diagnosis, therapies, and future directions","volume":"5","author":"Ghafourian K","year":"2020","unstructured":"Ghafourian K, Shapiro JS, Goodman L, Ardehali H. Iron and heart failure: diagnosis, therapies, and future directions. JACC Basic Transl Sci. 2020, 5:300-13. 10.1016\/j.jacbts.2019.08.009","journal-title":"JACC Basic Transl Sci"},{"key":"ref23","article-title":"Systolic heart failure: knowledge gaps, misconceptions, and future directions","volume":"14","author":"Samson R","year":"2014","unstructured":"Samson R, Ramachandran R, Le Jemtel TH. Systolic heart failure: knowledge gaps, misconceptions, and future directions. Ochsner J. 2014, 14:569-75.","journal-title":"Ochsner J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.12.034","article-title":"Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods","volume":"13","author":"Obokata M","year":"2020","unstructured":"Obokata M, Reddy YN, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020, 13:245-57. 10.1016\/j.jcmg.2018.12.034","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030846","article-title":"Acute heart failure: diagnostic-therapeutic pathways and preventive strategies\u2014a real-world clinician\u2019s guide","volume":"12","author":"Mauro C","year":"2023","unstructured":"Mauro C, Chianese S, Cocchia R, et al.. Acute heart failure: diagnostic-therapeutic pathways and preventive strategies\u2014a real-world clinician\u2019s guide. J Clin Med. 2023, 12:846. 10.3390\/jcm12030846","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2020-0095","article-title":"Adiponectin in heart failure","volume":"17","author":"Mado H","year":"2021","unstructured":"Mado H, Szczurek W, G\u0105sior M, Szygu\u0142a-Jurkiewicz B. Adiponectin in heart failure. Future Cardiol. 2021, 17:757-64. 10.2217\/fca-2020-0095","journal-title":"Future Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155090","article-title":"Hypertensive heart failure","volume":"12","author":"Triposkiadis F","year":"2023","unstructured":"Triposkiadis F, Sarafidis P, Briasoulis A, Magouliotis DE, Athanasiou T, Skoularigis J, Xanthopoulos A. Hypertensive heart failure. J Clin Med. 2023, 12:5090. 10.3390\/jcm12155090","journal-title":"J Clin Med"},{"key":"ref28","article-title":"Hypertensive Heart Disease","author":"Tackling G","year":"2024","unstructured":"Tackling G, Borhade MB. Hypertensive Heart Disease. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:20:2","article-title":"Heart failure in patients with diabetes mellitus","volume":"3","author":"Rosano GM","year":"2017","unstructured":"Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017, 3:52-5. 10.15420\/cfr.2016:20:2","journal-title":"Card Fail Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7229.236","article-title":"ABC of heart failure. Clinical features and complications","volume":"320","author":"Watson RD","year":"2000","unstructured":"Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ. 2000, 320:236-9. 10.1136\/bmj.320.7229.236","journal-title":"BMJ"},{"key":"ref31","article-title":"The role of beta-adrenergic blocking agents in preventing sudden cardiac death","volume":"85","author":"Pitt B","year":"1992","unstructured":"Pitt B. The role of beta-adrenergic blocking agents in preventing sudden cardiac death. Circulation. 1992, 85:I107-11.","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c110003","article-title":"Skeletal muscle changes in chronic cardiac disease and failure","volume":"5","author":"Kennel PJ","year":"2015","unstructured":"Kennel PJ, Mancini DM, Schulze PC. Skeletal muscle changes in chronic cardiac disease and failure. Compr Physiol. 2015, 5:1947-69. 10.1002\/cphy.c110003","journal-title":"Compr Physiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07015-8","article-title":"Wasting as independent risk factor for mortality in chronic heart failure","volume":"349","author":"Anker SD","year":"1997","unstructured":"Anker SD, Ponikowski P, Varney S, et al.. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997, 349:1050-3. 10.1016\/S0140-6736(96)07015-8","journal-title":"Lancet"},{"key":"ref34","article-title":"Natriuretic Peptide B Type Test","author":"Novack ML","year":"2024","unstructured":"Novack ML, Zubair M. Natriuretic Peptide B Type Test. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15166","article-title":"Assessment of the patient with heart failure symptoms and risk factors: a guide for the non-cardiologist","volume":"25","author":"Arnold SV","year":"2023","unstructured":"Arnold SV. Assessment of the patient with heart failure symptoms and risk factors: a guide for the non-cardiologist. Diabetes Obes Metab. 2023, 25:15-25. 10.1111\/dom.15166","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132771","article-title":"Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective","volume":"10","author":"Biasucci LM","year":"2021","unstructured":"Biasucci LM, Maino A, Grimaldi MC, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective. J Clin Med. 2021, 10:2771. 10.3390\/jcm10132771","journal-title":"J Clin Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2013.01.010","article-title":"Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients","volume":"19","author":"Wang YC","year":"2013","unstructured":"Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, Lin JL. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail. 2013, 19:163-8. 10.1016\/j.cardfail.2013.01.010","journal-title":"J Card Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.12.016","article-title":"Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure","volume":"5","author":"Aimo A","year":"2017","unstructured":"Aimo A, Vergaro G, Ripoli A, et al.. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017, 5:287-96. 10.1016\/j.jchf.2016.12.016","journal-title":"JACC Heart Fail"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.06.415","article-title":"Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure","volume":"14","author":"Boisot S","year":"2008","unstructured":"Boisot S, Beede J, Isakson S, et al.. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008, 14:732-8. 10.1016\/j.cardfail.2008.06.415","journal-title":"J Card Fail"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1159\/000338800","article-title":"Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure","volume":"122","author":"Manzano-Fern\u00e1ndez S","year":"2012","unstructured":"Manzano-Fern\u00e1ndez S, Januzzi JL, Pastor-P\u00e9rez FJ, et al.. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology. 2012, 122:158-66. 10.1159\/000338800","journal-title":"Cardiology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T","volume":"72","author":"Emdin M","year":"2018","unstructured":"Emdin M, Aimo A, Vergaro G, et al.. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018, 72:2309-20. 10.1016\/j.jacc.2018.08.2165","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/cc11440","article-title":"Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy","volume":"16","author":"Zilinski JL","year":"2012","unstructured":"Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi JL. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012, 16:R135. 10.1186\/cc11440","journal-title":"Crit Care"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.01.032","article-title":"Cardiac biomarkers in heart failure","volume":"47","author":"Liquori ME","year":"2014","unstructured":"Liquori ME, Christenson RH, Collinson PO, Defilippi CR. Cardiac biomarkers in heart failure. Clin Biochem. 2014, 47:327-37. 10.1016\/j.clinbiochem.2014.01.032","journal-title":"Clin Biochem"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic J","year":"2006","unstructured":"Dumic J, Dabelic S, Fl\u00f6gel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006, 1760:616-35. 10.1016\/j.bbagen.2005.12.020","journal-title":"Biochim Biophys Acta"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson NC","year":"2008","unstructured":"Henderson NC, Mackinnon AC, Farnworth SL, et al.. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008, 172:288-98. 10.2353\/ajpath.2008.070726","journal-title":"Am J Pathol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.12.001","article-title":"Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression","volume":"1853","author":"Song X","year":"2015","unstructured":"Song X, Qian X, Shen M, et al.. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta. 2015, 1853:513-21. 10.1016\/j.bbamcr.2014.12.001","journal-title":"Biochim Biophys Acta"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update","volume":"8","author":"Suthahar N","year":"2018","unstructured":"Suthahar N, Meijers WC, Sillj\u00e9 HH, Ho JE, Liu FT, de Boer RA. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics. 2018, 8:593-609. 10.7150\/thno.22196","journal-title":"Theranostics"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.05.081","article-title":"Galectin-3 in heart failure: high levels are associated with all-cause mortality","volume":"150","author":"Ueland T","year":"2011","unstructured":"Ueland T, Aukrust P, Broch K, Aakhus S, Sk\u00e5rdal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011, 150:361-4. 10.1016\/j.ijcard.2011.05.081","journal-title":"Int J Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho JE","year":"2012","unstructured":"Ho JE, Liu C, Lyass A, et al.. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012, 60:1249-56. 10.1016\/j.jacc.2012.04.053","journal-title":"J Am Coll Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.004374","article-title":"Galectin-3 in heart failure: more answers or more questions?","volume":"1","author":"Ahmad T","year":"2012","unstructured":"Ahmad T, Felker GM. Galectin-3 in heart failure: more answers or more questions?. J Am Heart Assoc. 2012, 1:e004374. 10.1161\/JAHA.112.004374","journal-title":"J Am Heart Assoc"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade RR","year":"2006","unstructured":"van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al.. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006, 48:1217-24. 10.1016\/j.jacc.2006.03.061","journal-title":"J Am Coll Cardiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study","volume":"167","author":"Daniels LB","year":"2014","unstructured":"Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study. Am Heart J. 2014, 167:674-82.e1. 10.1016\/j.ahj.2013.12.031","journal-title":"Am Heart J"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer RA","year":"2012","unstructured":"de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al.. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012, 272:55-64. 10.1111\/j.1365-2796.2011.02476.x","journal-title":"J Intern Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2019.1671188","article-title":"An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure","volume":"19","author":"Darden D","year":"2019","unstructured":"Darden D, Nishimura M, Sharim J, Maisel A. An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. Expert Rev Mol Diagn. 2019, 19:1019-29. 10.1080\/14737159.2019.1671188","journal-title":"Expert Rev Mol Diagn"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy CW","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017, 136:e137-61. 10.1161\/CIR.0000000000000509","journal-title":"Circulation"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok DJ","year":"2010","unstructured":"Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010, 99:323-8. 10.1007\/s00392-010-0125-y","journal-title":"Clin Res Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang WH","year":"2011","unstructured":"Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011, 108:385-90. 10.1016\/j.amjcard.2011.03.056","journal-title":"Am J Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis: the need for a reappraisal","volume":"65","author":"L\u00f3pez B","year":"2015","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, Ravassa S, et al.. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol. 2015, 65:2449-56. 10.1016\/j.jacc.2015.04.026","journal-title":"J Am Coll Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.696","article-title":"Myocardial fibrosis: biomedical research from bench to bedside","volume":"19","author":"Gy\u00f6ngy\u00f6si M","year":"2017","unstructured":"Gy\u00f6ngy\u00f6si M, Winkler J, Ramos I, et al.. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017, 19:177-91. 10.1002\/ejhf.696","journal-title":"Eur J Heart Fail"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure: biological and translational perspectives","volume":"71","author":"Gonz\u00e1lez A","year":"2018","unstructured":"Gonz\u00e1lez A, Schelbert EB, D\u00edez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018, 71:1696-706. 10.1016\/j.jacc.2018.02.021","journal-title":"J Am Coll Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher G","year":"1995","unstructured":"Klappacher G, Franzen P, Haab D, et al.. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995, 75:913-8. 10.1016\/S0002-9149(99)80686-9","journal-title":"Am J Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2828(89)90778-5","article-title":"Patterns of myocardial fibrosis","volume":"21","author":"Weber KT","year":"1989","unstructured":"Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Mol Cell Cardiol. 1989, 21:121-31. 10.1016\/0022-2828(89)90778-5","journal-title":"J Mol Cell Cardiol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2459\/01.JCM.0000435617.86180.0b","article-title":"Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure","volume":"15","author":"L\u00f6fsj\u00f6g\u00e5rd J","year":"2014","unstructured":"L\u00f6fsj\u00f6g\u00e5rd J, Kahan T, D\u00edez J, et al.. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med (Hagerstown). 2014, 15:463-9. 10.2459\/01.JCM.0000435617.86180.0b","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum H","year":"2011","unstructured":"Krum H, Elsik M, Schneider HG, et al.. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011, 4:561-8. 10.1161\/CIRCHEARTFAILURE.110.960716","journal-title":"Circ Heart Fail"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.07.006","article-title":"Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure","volume":"164","author":"Flevari P","year":"2012","unstructured":"Flevari P, Theodorakis G, Leftheriotis D, et al.. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. Am Heart J. 2012, 164:530-7. 10.1016\/j.ahj.2012.07.006","journal-title":"Am Heart J"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1159\/000328686","article-title":"Role of endothelin in thick ascending limb sodium chloride transport","volume":"172","author":"Ramseyer VD","year":"2011","unstructured":"Ramseyer VD, Cabral PD, Garvin JL. Role of endothelin in thick ascending limb sodium chloride transport. Contrib Nephrol. 2011, 172:76-83. 10.1159\/000328686","journal-title":"Contrib Nephrol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.063","article-title":"Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure","volume":"67","author":"L\u00f3pez B","year":"2016","unstructured":"L\u00f3pez B, Ravassa S, Gonz\u00e1lez A, et al.. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol. 2016, 67:251-60. 10.1016\/j.jacc.2015.10.063","journal-title":"J Am Coll Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2006.02.013","article-title":"The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"12","author":"Masson S","year":"2006","unstructured":"Masson S, Latini R, Anand IS, et al.. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2006, 12:375-80. 10.1016\/j.cardfail.2006.02.013","journal-title":"J Card Fail"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13064","article-title":"Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure","volume":"7","author":"Zymli\u0144ski R","year":"2020","unstructured":"Zymli\u0144ski R, Sierpi\u0144ski R, Metra M, et al.. Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. ESC Heart Fail. 2020, 7:3536-44. 10.1002\/ehf2.13064","journal-title":"ESC Heart Fail"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021426","article-title":"Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction","volume":"197","author":"Askari AT","year":"2003","unstructured":"Askari AT, Brennan ML, Zhou X, et al.. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003, 197:615-24. 10.1084\/jem.20021426","journal-title":"J Exp Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"98","author":"Tang WH","year":"2006","unstructured":"Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, Hazen SL. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006, 98:796-9. 10.1016\/j.amjcard.2006.04.018","journal-title":"Am J Cardiol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.01.026","article-title":"Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure","volume":"103","author":"Tang WH","year":"2009","unstructured":"Tang WH, Katz R, Brennan ML, Aviles RJ, Tracy RP, Psaty BM, Hazen SL. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol. 2009, 103:1269-74. 10.1016\/j.amjcard.2009.01.026","journal-title":"Am J Cardiol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-019-00450-1","article-title":"Reappraisal of inflammatory biomarkers in heart failure","volume":"17","author":"Chaikijurajai T","year":"2020","unstructured":"Chaikijurajai T, Tang WH. Reappraisal of inflammatory biomarkers in heart failure. Curr Heart Fail Rep. 2020, 17:9-19. 10.1007\/s11897-019-00450-1","journal-title":"Curr Heart Fail Rep"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.053","article-title":"Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure","volume":"49","author":"Tang WH","year":"2007","unstructured":"Tang WH, Tong W, Troughton RW, et al.. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007, 49:2364-70. 10.1016\/j.jacc.2007.02.053","journal-title":"J Am Coll Cardiol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2001.d01-148.x","article-title":"Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy","volume":"89","author":"Sayed-Ahmed MM","year":"2001","unstructured":"Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001, 89:140-4. 10.1034\/j.1600-0773.2001.d01-148.x","journal-title":"Pharmacol Toxicol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky B","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, et al.. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014, 63:809-16. 10.1016\/j.jacc.2013.10.061","journal-title":"J Am Coll Cardiol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.2174\/1573403x12666160111125304","article-title":"GDF 15 - a novel biomarker in the offing for heart failure","volume":"12","author":"George M","year":"2016","unstructured":"George M, Jena A, Srivatsan V, Muthukumar R, Dhandapani VE. GDF 15 - a novel biomarker in the offing for heart failure. Curr Cardiol Rev. 2016, 12:37-46. 10.2174\/1573403x12666160111125304","journal-title":"Curr Cardiol Rev"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.11.089","article-title":"Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction","volume":"166","author":"Manhenke C","year":"2013","unstructured":"Manhenke C, \u00d8rn S, von Haehling S, et al.. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol. 2013, 166:729-35. 10.1016\/j.ijcard.2011.11.089","journal-title":"Int J Cardiol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.201210","article-title":"Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals","volume":"59","author":"Eggers KM","year":"2013","unstructured":"Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem. 2013, 59:1091-8. 10.1373\/clinchem.2012.201210","journal-title":"Clin Chem"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri A","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009, 23:215-24. 10.1038\/leu.2008.307","journal-title":"Leukemia"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.04.121","article-title":"The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases","volume":"91","author":"Esparvarinha M","year":"2017","unstructured":"Esparvarinha M, Nickho H, Mohammadi H, Aghebati-Maleki L, Abdolalizadeh J, Majidi J. The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomed Pharmacother. 2017, 91:632-44. 10.1016\/j.biopha.2017.04.121","journal-title":"Biomed Pharmacother"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2227","article-title":"Elevated serum free light chains predict cardiovascular events in type 2 diabetes","volume":"37","author":"Bellary S","year":"2014","unstructured":"Bellary S, Faint JM, Assi LK, Hutchison CA, Harding SJ, Raymond NT, Barnett AH. Elevated serum free light chains predict cardiovascular events in type 2 diabetes. Diabetes Care. 2014, 37:2028-30. 10.2337\/dc13-2227","journal-title":"Diabetes Care"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.105","article-title":"Free light chains in patients with acute coronary syndromes: relationships to inflammation and renal function","volume":"185","author":"Shantsila E","year":"2015","unstructured":"Shantsila E, Tapp LD, Lip GY. Free light chains in patients with acute coronary syndromes: relationships to inflammation and renal function. Int J Cardiol. 2015, 185:322-7. 10.1016\/j.ijcard.2015.03.105","journal-title":"Int J Cardiol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.07.049","article-title":"Free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease","volume":"114","author":"Shantsila E","year":"2014","unstructured":"Shantsila E, Wrigley B, Lip GY. Free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease. Am J Cardiol. 2014, 114:1243-8. 10.1016\/j.amjcard.2014.07.049","journal-title":"Am J Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12159","article-title":"The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease","volume":"36","author":"Burmeister A","year":"2014","unstructured":"Burmeister A, Assi LK, Ferro CJ, et al.. The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease. Int J Lab Hematol. 2014, 36:415-24. 10.1111\/ijlh.12159","journal-title":"Int J Lab Hematol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000136085.34185.83","article-title":"Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats","volume":"110","author":"Nakamura R","year":"2004","unstructured":"Nakamura R, Kato J, Kitamura K, et al.. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation. 2004, 110:426-31. 10.1161\/01.CIR.0000136085.34185.83","journal-title":"Circulation"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1366","article-title":"Adrenomedullin in heart failure: pathophysiology and therapeutic application","volume":"21","author":"Voors AA","year":"2019","unstructured":"Voors AA, Kremer D, Geven C, et al.. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019, 21:163-71. 10.1002\/ejhf.1366","journal-title":"Eur J Heart Fail"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1904","article-title":"Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure","volume":"21","author":"Pousset F","year":"2000","unstructured":"Pousset F, Masson F, Chavirovskaia O, et al.. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J. 2000, 21:1009-14. 10.1053\/euhj.1999.1904","journal-title":"Eur Heart J"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01724.x","article-title":"Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure","volume":"36","author":"Stoiser B","year":"2006","unstructured":"Stoiser B, M\u00f6rtl D, H\u00fclsmann M, et al.. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006, 36:771-8. 10.1111\/j.1365-2362.2006.01724.x","journal-title":"Eur J Clin Invest"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.10.001","article-title":"Copeptin in heart failure: review and meta-analysis","volume":"475","author":"Zhong Y","year":"2017","unstructured":"Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure: review and meta-analysis. Clin Chim Acta. 2017, 475:36-43. 10.1016\/j.cca.2017.10.001","journal-title":"Clin Chim Acta"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang KC","year":"2011","unstructured":"Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011, 43:904-14. 10.1016\/j.molcel.2011.08.018","journal-title":"Mol Cell"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201100084","article-title":"Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs","volume":"33","author":"Saxena A","year":"2011","unstructured":"Saxena A, Carninci P. Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs. Bioessays. 2011, 33:830-9. 10.1002\/bies.201100084","journal-title":"Bioessays"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.112.146704","article-title":"Long noncoding RNAs: past, present, and future","volume":"193","author":"Kung JT","year":"2013","unstructured":"Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013, 193:651-69. 10.1534\/genetics.112.146704","journal-title":"Genetics"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07611-z","article-title":"Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population","volume":"7","author":"Zhang Z","year":"2017","unstructured":"Zhang Z, Gao W, Long QQ, et al.. Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep. 2017, 7:7491. 10.1038\/s41598-017-07611-z","journal-title":"Sci Rep"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.11.011","article-title":"The lncRNA H19\/miR-675 axis regulates myocardial ischemic and reperfusion injury by targeting PPAR\u03b1","volume":"105","author":"Luo H","year":"2019","unstructured":"Luo H, Wang J, Liu D, et al.. The lncRNA H19\/miR-675 axis regulates myocardial ischemic and reperfusion injury by targeting PPAR\u03b1. Mol Immunol. 2019, 105:46-54. 10.1016\/j.molimm.2018.11.011","journal-title":"Mol Immunol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai9118","article-title":"The long noncoding RNA Wisper controls cardiac fibrosis and remodeling","volume":"9","author":"Micheletti R","year":"2017","unstructured":"Micheletti R, Plaisance I, Abraham BJ, et al.. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med. 2017, 9:eaai9118. 10.1126\/scitranslmed.aai9118","journal-title":"Sci Transl Med"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4179","article-title":"The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy","volume":"22","author":"Wang Z","year":"2016","unstructured":"Wang Z, Zhang XJ, Ji YX, et al.. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med. 2016, 22:1131-9. 10.1038\/nm.4179","journal-title":"Nat Med"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1475","article-title":"Long noncoding RNA Chast promotes cardiac remodeling","volume":"8","author":"Viereck J","year":"2016","unstructured":"Viereck J, Kumarswamy R, Foinquinos A, et al.. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016, 8:326ra22. 10.1126\/scitranslmed.aaf1475","journal-title":"Sci Transl Med"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142447","article-title":"A common allele on chromosome 9 associated with coronary heart disease","volume":"316","author":"McPherson R","year":"2007","unstructured":"McPherson R, Pertsemlidis A, Kavaslar N, et al.. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007, 316:1488-91. 10.1126\/science.1142447","journal-title":"Science"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29162","article-title":"Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress","volume":"120","author":"Dai W","year":"2019","unstructured":"Dai W, Lee D. Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress. J Cell Biochem. 2019, 120:18446-56. 10.1002\/jcb.29162","journal-title":"J Cell Biochem"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.10.136","article-title":"Down-regulation of lncRNA MALAT1 reduces cardiomyocyte apoptosis and improves left ventricular function in diabetic rats","volume":"203","author":"Zhang M","year":"2016","unstructured":"Zhang M, Gu H, Xu W, Zhou X. Down-regulation of lncRNA MALAT1 reduces cardiomyocyte apoptosis and improves left ventricular function in diabetic rats. Int J Cardiol. 2016, 203:214-6. 10.1016\/j.ijcard.2015.10.136","journal-title":"Int J Cardiol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1038\/srep37354","article-title":"Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes","volume":"6","author":"de Gonzalo-Calvo D","year":"2016","unstructured":"de Gonzalo-Calvo D, Kenneweg F, Bang C, et al.. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep. 2016, 6:37354. 10.1038\/srep37354","journal-title":"Sci Rep"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2018.11.004","article-title":"Identification and regulation of the long non-coding RNA Heat2 in heart failure","volume":"126","author":"Boeckel JN","year":"2019","unstructured":"Boeckel JN, Perret MF, Glaser SF, et al.. Identification and regulation of the long non-coding RNA Heat2 in heart failure. J Mol Cell Cardiol. 2019, 126:13-22. 10.1016\/j.yjmcc.2018.11.004","journal-title":"J Mol Cell Cardiol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00205-14","article-title":"Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1\u03b1 at chromatin","volume":"34","author":"Boros J","year":"2014","unstructured":"Boros J, Arnoult N, Stroobant V, Collet JF, Decottignies A. Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1\u03b1 at chromatin. Mol Cell Biol. 2014, 34:3662-74. 10.1128\/MCB.00205-14","journal-title":"Mol Cell Biol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2015.066","article-title":"Long noncoding RNA MHRT protects cardiomyocytes against H2O2-induced apoptosis","volume":"24","author":"Zhang J","year":"2016","unstructured":"Zhang J, Gao C, Meng M, Tang H. Long noncoding RNA MHRT protects cardiomyocytes against H2O2-induced apoptosis. Biomol Ther (Seoul). 2016, 24:19-24. 10.4062\/biomolther.2015.066","journal-title":"Biomol Ther (Seoul)"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1038\/nature13596","article-title":"A long noncoding RNA protects the heart from pathological hypertrophy","volume":"514","author":"Han P","year":"2014","unstructured":"Han P, Li W, Lin CH, et al.. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014, 514:102-6. 10.1038\/nature13596","journal-title":"Nature"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0926-5","article-title":"Long noncoding RNA dysregulation in ischemic heart failure","volume":"14","author":"Greco S","year":"2016","unstructured":"Greco S, Zaccagnini G, Perfetti A, et al.. Long noncoding RNA dysregulation in ischemic heart failure. J Transl Med. 2016, 14:183. 10.1186\/s12967-016-0926-5","journal-title":"J Transl Med"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1186\/1476-7120-5-34","article-title":"Role of echocardiography in diagnosis and risk stratification in heart failure with left ventricular systolic dysfunction","volume":"5","author":"Ciampi Q","year":"2007","unstructured":"Ciampi Q, Villari B. Role of echocardiography in diagnosis and risk stratification in heart failure with left ventricular systolic dysfunction. Cardiovasc Ultrasound. 2007, 5:34. 10.1186\/1476-7120-5-34","journal-title":"Cardiovasc Ultrasound"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.74.4.815","article-title":"The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy","volume":"74","author":"Carroll JD","year":"1986","unstructured":"Carroll JD, Lang RM, Neumann AL, Borow KM, Rajfer SI. The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy. Circulation. 1986, 74:815-25. 10.1161\/01.cir.74.4.815","journal-title":"Circulation"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1259\/bjro.20220026","article-title":"Imaging in patients with acute dyspnea when cardiac or pulmonary origin is suspected","volume":"5","author":"Milos RI","year":"2023","unstructured":"Milos RI, Bartha C, R\u00f6hrich S, et al.. Imaging in patients with acute dyspnea when cardiac or pulmonary origin is suspected. BJR Open. 2023, 5:20220026. 10.1259\/bjro.20220026","journal-title":"BJR Open"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1111\/echo.14877","article-title":"Comparison of echocardiographic parameters with cardiac magnetic resonance imaging in the assessment of right ventricular function","volume":"37","author":"Agasthi P","year":"2020","unstructured":"Agasthi P, Chao CJ, Siegel RJ, et al.. Comparison of echocardiographic parameters with cardiac magnetic resonance imaging in the assessment of right ventricular function. Echocardiography. 2020, 37:1792-802. 10.1111\/echo.14877","journal-title":"Echocardiography"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2019.06.02","article-title":"Cardiovascular magnetic resonance imaging for structural heart disease","volume":"10","author":"Situ Y","year":"2020","unstructured":"Situ Y, Birch SC, Moreyra C, Holloway CJ. Cardiovascular magnetic resonance imaging for structural heart disease. Cardiovasc Diagn Ther. 2020, 10:361-75. 10.21037\/cdt.2019.06.02","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27848","article-title":"Emerging techniques in cardiac magnetic resonance imaging","volume":"55","author":"Guo R","year":"2022","unstructured":"Guo R, Weing\u00e4rtner S, \u0160iuryt\u0117 P, et al.. Emerging techniques in cardiac magnetic resonance imaging. J Magn Reson Imaging. 2022, 55:1043-59. 10.1002\/jmri.27848","journal-title":"J Magn Reson Imaging"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2021.107391","article-title":"Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication","volume":"56","author":"Giordano C","year":"2022","unstructured":"Giordano C, Francone M, Cundari G, Pisano A, d'Amati G. Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication. Cardiovasc Pathol. 2022, 56:107391. 10.1016\/j.carpath.2021.107391","journal-title":"Cardiovasc Pathol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61608-9","article-title":"Left ventricular global function index by magnetic resonance imaging - a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy","volume":"10","author":"Huang S","year":"2020","unstructured":"Huang S, Xu HY, Diao KY, et al.. Left ventricular global function index by magnetic resonance imaging - a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy. Sci Rep. 2020, 10:4707. 10.1038\/s41598-020-61608-9","journal-title":"Sci Rep"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3390\/tomography7040075","article-title":"Diastolic cardiac function by MRI\u2014imaging capabilities and clinical applications","volume":"7","author":"Ibrahim EH","year":"2021","unstructured":"Ibrahim EH, Dennison J, Frank L, Stojanovska J. Diastolic cardiac function by MRI\u2014imaging capabilities and clinical applications. Tomography. 2021, 7:893-914. 10.3390\/tomography7040075","journal-title":"Tomography"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.2463\/mrms.rev.2021-0011","article-title":"MR imaging in the 21st century: technical innovation over the first two decades","volume":"21","author":"Kabasawa H","year":"2022","unstructured":"Kabasawa H. MR imaging in the 21st century: technical innovation over the first two decades. Magn Reson Med Sci. 2022, 21:71-82. 10.2463\/mrms.rev.2021-0011","journal-title":"Magn Reson Med Sci"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-020-00481-z","article-title":"Cardiovascular magnetic resonance for the differentiation of left ventricular hypertrophy","volume":"17","author":"Burrage MK","year":"2020","unstructured":"Burrage MK, Ferreira VM. Cardiovascular magnetic resonance for the differentiation of left ventricular hypertrophy. Curr Heart Fail Rep. 2020, 17:192-204. 10.1007\/s11897-020-00481-z","journal-title":"Curr Heart Fail Rep"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2021.05.008","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for cardiac transplant rejection: a meta-analysis","volume":"14","author":"Han D","year":"2021","unstructured":"Han D, Miller RJ, Otaki Y, et al.. Diagnostic accuracy of cardiovascular magnetic resonance for cardiac transplant rejection: a meta-analysis. JACC Cardiovasc Imaging. 2021, 14:2337-49. 10.1016\/j.jcmg.2021.05.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.006309","article-title":"Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy","volume":"10","author":"Hindieh W","year":"2017","unstructured":"Hindieh W, Weissler-Snir A, Hammer H, Adler A, Rakowski H, Chan RH. Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017, 10:10.1161\/CIRCIMAGING.117.006309","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2019.09.005","article-title":"Left ventricular hypertrophy: evaluation with cardiac MRI","volume":"49","author":"Grajewski KG","year":"2020","unstructured":"Grajewski KG, Stojanovska J, Ibrahim EH, Sayyouh M, Attili A. Left ventricular hypertrophy: evaluation with cardiac MRI. Curr Probl Diagn Radiol. 2020, 49:460-75. 10.1067\/j.cpradiol.2019.09.005","journal-title":"Curr Probl Diagn Radiol"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13142461","article-title":"Diagnostic role of native T1 mapping compared to conventional magnetic resonance techniques in cardiac disease in a real-life cohort","volume":"13","author":"Aquaro GD","year":"2023","unstructured":"Aquaro GD, Monastero S, Todiere G, et al.. Diagnostic role of native T1 mapping compared to conventional magnetic resonance techniques in cardiac disease in a real-life cohort. Diagnostics (Basel). 2023, 13:2461. 10.3390\/diagnostics13142461","journal-title":"Diagnostics (Basel)"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.013","article-title":"T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients","volume":"50","author":"Poindron V","year":"2020","unstructured":"Poindron V, Chatelus E, Canuet M, et al.. T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Semin Arthritis Rheum. 2020, 50:128-34. 10.1016\/j.semarthrit.2019.06.013","journal-title":"Semin Arthritis Rheum"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-020-00738-w","article-title":"Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail","volume":"12","author":"Hassan S","year":"2020","unstructured":"Hassan S, Barrett CJ, Crossman DJ. Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail. Biophys Rev. 2020, 12:969-87. 10.1007\/s12551-020-00738-w","journal-title":"Biophys Rev"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-023-00945-w","article-title":"A simplified method to correct saturation of arterial input function for cardiac magnetic resonance first-pass perfusion imaging: validation with simultaneously acquired PET","volume":"25","author":"Li R","year":"2023","unstructured":"Li R, Edalati M, Muccigrosso D, Lau JM, Laforest R, Woodard PK, Zheng J. A simplified method to correct saturation of arterial input function for cardiac magnetic resonance first-pass perfusion imaging: validation with simultaneously acquired PET. J Cardiovasc Magn Reson. 2023, 25:35. 10.1186\/s12968-023-00945-w","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2020.11.011","article-title":"Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"76","author":"Assadi H","year":"2021","unstructured":"Assadi H, Jones R, Swift AJ, Al-Mohammad A, Garg P. Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: a systematic review and meta-analysis. Magn Reson Imaging. 2021, 76:116-22. 10.1016\/j.mri.2020.11.011","journal-title":"Magn Reson Imaging"},{"key":"ref127","article-title":"Role of stress echocardiography in assessment of myocardial viability and contractile reserve","volume":"20","author":"El-Sayed ZH","year":"2022","unstructured":"El-Sayed ZH, El-Samei MMA, Mohamed GI, Mohamed MM. Role of stress echocardiography in assessment of myocardial viability and contractile reserve. NeuroQuantology. 2022, 20:964-8.","journal-title":"NeuroQuantology"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeab053","article-title":"Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI)","volume":"22","author":"Almeida AG","year":"2021","unstructured":"Almeida AG, Carpenter JP, Cameli M, et al.. Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2021, 22:e97-125. 10.1093\/ehjci\/jeab053","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52058-8","article-title":"Quantification of myocardial scar of different etiology using dark- and bright-blood late gadolinium enhancement cardiovascular magnetic resonance","volume":"14","author":"Jada L","year":"2024","unstructured":"Jada L, Holtackers RJ, Martens B, et al.. Quantification of myocardial scar of different etiology using dark- and bright-blood late gadolinium enhancement cardiovascular magnetic resonance. Sci Rep. 2024, 14:5395. 10.1038\/s41598-024-52058-8","journal-title":"Sci Rep"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2020.06.011","article-title":"Prognostic value of late gadolinium enhancement in cardiac MRI of non-ischemic dilated cardiomyopathy patients","volume":"72","author":"Behera DR","year":"2020","unstructured":"Behera DR, Kumar VKA, Namboodiri KKN, et al.. Prognostic value of late gadolinium enhancement in cardiac MRI of non-ischemic dilated cardiomyopathy patients. Indian Heart J. 2020, 72:362-8. 10.1016\/j.ihj.2020.06.011","journal-title":"Indian Heart J"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2022.02.006","article-title":"Myocardial tissue imaging with cardiovascular magnetic resonance","volume":"80","author":"Nakamori S","year":"2022","unstructured":"Nakamori S, Dohi K. Myocardial tissue imaging with cardiovascular magnetic resonance. J Cardiol. 2022, 80:377-85. 10.1016\/j.jjcc.2022.02.006","journal-title":"J Cardiol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.3390\/math10050731","article-title":"An optimal H-infinity controller for left ventricular assist devices based on a Starling-like controller: a simulation study","volume":"10","author":"Bakouri M","year":"2022","unstructured":"Bakouri M, Alassaf A, Alshareef K, Abdelsalam S, Ismail HF, Ganoun A, Alomari AH. An optimal H-infinity controller for left ventricular assist devices based on a Starling-like controller: a simulation study. Mathematics. 2022, 10:731. 10.3390\/math10050731","journal-title":"Mathematics"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2020.05.052","article-title":"Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how, and when","volume":"13","author":"Ford TJ","year":"2020","unstructured":"Ford TJ, Ong P, Sechtem U, et al.. Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how, and when. JACC Cardiovasc Interv. 2020, 13:1847-64. 10.1016\/j.jcin.2020.05.052","journal-title":"JACC Cardiovasc Interv"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009101","article-title":"Invasive right ventricular pressure-volume analysis: basic principles, clinical applications, and practical recommendations","volume":"15","author":"Brener MI","year":"2022","unstructured":"Brener MI, Masoumi A, Ng VG, et al.. Invasive right ventricular pressure-volume analysis: basic principles, clinical applications, and practical recommendations. Circ Heart Fail. 2022, 15:e009101. 10.1161\/CIRCHEARTFAILURE.121.009101","journal-title":"Circ Heart Fail"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.08.009","article-title":"Standardization of the right heart catheterization and the emerging role of advanced hemodynamics in heart failure","volume":"29","author":"Grinstein J","year":"2023","unstructured":"Grinstein J, Houston BA, Nguyen AB, et al.. Standardization of the right heart catheterization and the emerging role of advanced hemodynamics in heart failure. J Card Fail. 2023, 29:1543-55. 10.1016\/j.cardfail.2023.08.009","journal-title":"J Card Fail"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28491","article-title":"Invasive hemodynamic assessment of patients with submassive pulmonary embolism","volume":"95","author":"Khandhar SJ","year":"2020","unstructured":"Khandhar SJ, Mehta M, Cilia L, Palevsky H, Matthai W, Rivera-Lebron B, Toma C. Invasive hemodynamic assessment of patients with submassive pulmonary embolism. Catheter Cardiovasc Interv. 2020, 95:13-8. 10.1002\/ccd.28491","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.09.049","article-title":"Cardiac output estimation using pulse wave analysis\u2014physiology, algorithms, and technologies: a narrative review","volume":"126","author":"Saugel B","year":"2021","unstructured":"Saugel B, Kouz K, Scheeren TW, Greiwe G, Hoppe P, Romagnoli S, de Backer D. Cardiac output estimation using pulse wave analysis\u2014physiology, algorithms, and technologies: a narrative review. Br J Anaesth. 2021, 126:67-76. 10.1016\/j.bja.2020.09.049","journal-title":"Br J Anaesth"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.045409","article-title":"Altered hemodynamics and end-organ damage in heart failure: Impact on the lung and kidney","volume":"142","author":"Verbrugge FH","year":"2020","unstructured":"Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered hemodynamics and end-organ damage in heart failure: Impact on the lung and kidney. Circulation. 2020, 142:998-1012. 10.1161\/CIRCULATIONAHA.119.045409","journal-title":"Circulation"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.07.012","article-title":"Hemodynamics for the heart failure clinician: a state-of-the-art review","volume":"28","author":"Hsu S","year":"2022","unstructured":"Hsu S, Fang JC, Borlaug BA. Hemodynamics for the heart failure clinician: a state-of-the-art review. J Card Fail. 2022, 28:133-48. 10.1016\/j.cardfail.2021.07.012","journal-title":"J Card Fail"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcct.2020.11.001","article-title":"SCCT 2021 expert consensus document on coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography","volume":"15","author":"Narula J","year":"2021","unstructured":"Narula J, Chandrashekhar Y, Ahmadi A, et al.. SCCT 2021 expert consensus document on coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2021, 15:192-217. 10.1016\/j.jcct.2020.11.001","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000601","article-title":"Recent and upcoming technological developments in computed tomography: high speed, low dose, deep learning, multienergy","volume":"55","author":"Lell MM","year":"2020","unstructured":"Lell MM, Kachelrie\u00df M. Recent and upcoming technological developments in computed tomography: high speed, low dose, deep learning, multienergy. Invest Radiol. 2020, 55:8-19. 10.1097\/RLI.0000000000000601","journal-title":"Invest Radiol"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.120.245308","article-title":"Considerations for stress testing performed in conjunction with myocardial perfusion imaging","volume":"48","author":"Mann A","year":"2020","unstructured":"Mann A, Williams J. Considerations for stress testing performed in conjunction with myocardial perfusion imaging. J Nucl Med Technol. 2020, 48:114-21. 10.2967\/jnmt.120.245308","journal-title":"J Nucl Med Technol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-021-02546-5","article-title":"Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test","volume":"29","author":"Yang H","year":"2022","unstructured":"Yang H, Faust E, Gao E, et al.. Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test. J Nucl Cardiol. 2022, 29:1788-95. 10.1007\/s12350-021-02546-5","journal-title":"J Nucl Cardiol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12940","article-title":"Regadenoson stress testing: a comprehensive review with a focused update","volume":"13","author":"Elkholy KO","year":"2021","unstructured":"Elkholy KO, Hegazy O, Okunade A, Aktas S, Ajibawo T. Regadenoson stress testing: a comprehensive review with a focused update. Cureus. 2021, 13:e12940. 10.7759\/cureus.12940","journal-title":"Cureus"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117 J","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, et al.. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020, 22:1504-24. 10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168939","article-title":"New progress in early diagnosis of atherosclerosis","volume":"23","author":"Meng H","year":"2022","unstructured":"Meng H, Ruan J, Yan Z, Chen Y, Liu J, Li X, Meng F. New progress in early diagnosis of atherosclerosis. Int J Mol Sci. 2022, 23:8939. 10.3390\/ijms23168939","journal-title":"Int J Mol Sci"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/s0147-9563(97)90053-4","article-title":"Older adults' symptoms and their duration before hospitalization for heart failure","volume":"26","author":"Friedman MM","year":"1997","unstructured":"Friedman MM. Older adults' symptoms and their duration before hospitalization for heart failure. Heart Lung. 1997, 26:169-76. 10.1016\/s0147-9563(97)90053-4","journal-title":"Heart Lung"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1002\/nur.20118","article-title":"Somatic awareness, uncertainty, and delay in care-seeking in acute heart failure","volume":"29","author":"Jurgens CY","year":"2006","unstructured":"Jurgens CY. Somatic awareness, uncertainty, and delay in care-seeking in acute heart failure. Res Nurs Health. 2006, 29:74-86. 10.1002\/nur.20118","journal-title":"Res Nurs Health"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1097\/00012272-199703000-00003","article-title":"The middle-range theory of unpleasant symptoms: an update","volume":"19","author":"Lenz ER","year":"1997","unstructured":"Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997, 19:14-27. 10.1097\/00012272-199703000-00003","journal-title":"ANS Adv Nurs Sci"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1097\/00012272-199503000-00003","article-title":"Collaborative development of middle-range nursing theories: toward a theory of unpleasant symptoms","volume":"17","author":"Lenz ER","year":"1995","unstructured":"Lenz ER, Suppe F, Gift AG, Pugh LC, Milligan RA. Collaborative development of middle-range nursing theories: toward a theory of unpleasant symptoms. ANS Adv Nurs Sci. 1995, 17:1-13. 10.1097\/00012272-199503000-00003","journal-title":"ANS Adv Nurs Sci"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2016.05.014","article-title":"Symptom clusters and quality of life among patients with advanced heart failure","volume":"13","author":"Yu DS","year":"2016","unstructured":"Yu DS, Chan HY, Leung DY, Hui E, Sit JW. Symptom clusters and quality of life among patients with advanced heart failure. J Geriatr Cardiol. 2016, 13:408-14. 10.11909\/j.issn.1671-5411.2016.05.014","journal-title":"J Geriatr Cardiol"},{"key":"ref152","article-title":"Cardiac Nursing: A Companion to Braunwald's Heart Disease","author":"Moser DK","year":"2008","unstructured":"Moser DK, Riegel B. Cardiac Nursing: A Companion to Braunwald's Heart Disease. Elsevier Health Sciences, St. Louis, MO; 2008."},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030857","article-title":"Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity?","volume":"11","author":"Severino P","year":"2022","unstructured":"Severino P, D'Amato A, Prosperi S, et al.. Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity?. J Clin Med. 2022, 11:857. 10.3390\/jcm11030857","journal-title":"J Clin Med"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031020","article-title":"Heart failure pharmacological management: gaps and current perspectives","volume":"12","author":"Severino P","year":"2023","unstructured":"Severino P, D'Amato A, Prosperi S, et al.. Heart failure pharmacological management: gaps and current perspectives. J Clin Med. 2023, 12:1020. 10.3390\/jcm12031020","journal-title":"J Clin Med"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth OA","year":"2022","unstructured":"Smiseth OA, Morris DA, Cardim N, et al.. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022, 23:e34-61. 10.1093\/ehjci\/jeab154","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247641","article-title":"Multimodality imaging in advanced heart failure for diagnosis, management and follow-up: a comprehensive review","volume":"12","author":"Pergola V","year":"2023","unstructured":"Pergola V, Cameli M, Mattesi G, et al.. Multimodality imaging in advanced heart failure for diagnosis, management and follow-up: a comprehensive review. J Clin Med. 2023, 12:7641. 10.3390\/jcm12247641","journal-title":"J Clin Med"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suad052","article-title":"Multimodality imaging in decompensated heart failure","volume":"25","author":"D'Andrea A","year":"2023","unstructured":"D'Andrea A, Ilardi F, Palermi S, et al.. Multimodality imaging in decompensated heart failure. Eur Heart J Suppl. 2023, 25:C292-300. 10.1093\/eurheartjsupp\/suad052","journal-title":"Eur Heart J Suppl"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1186\/s44156-024-00051-2","article-title":"The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography","volume":"11","author":"Robinson S","year":"2024","unstructured":"Robinson S, Ring L, Oxborough D, et al.. The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography. Echo Res Pract. 2024, 11:16. 10.1186\/s44156-024-00051-2","journal-title":"Echo Res Pract"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.01.011","article-title":"Artificial intelligence in medicine","volume":"69","author":"Hamet P","year":"2017","unstructured":"Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017, 69:S36-40. 10.1016\/j.metabol.2017.01.011","journal-title":"Metabolism"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar A","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019, 380:1347-58. 10.1056\/NEJMra1814259","journal-title":"N Engl J Med"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging9020050","article-title":"The role of artificial intelligence in echocardiography","volume":"9","author":"Barry T","year":"2023","unstructured":"Barry T, Farina JM, Chao CJ, et al.. The role of artificial intelligence in echocardiography. J Imaging. 2023, 9:50. 10.3390\/jimaging9020050","journal-title":"J Imaging"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.06.004","article-title":"Using machine learning to predict one-year cardiovascular events in patients with severe dilated cardiomyopathy","volume":"117","author":"Chen R","year":"2019","unstructured":"Chen R, Lu A, Wang J, et al.. Using machine learning to predict one-year cardiovascular events in patients with severe dilated cardiomyopathy. Eur J Radiol. 2019, 117:178-83. 10.1016\/j.ejrad.2019.06.004","journal-title":"Eur J Radiol"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2020.01.009","article-title":"Deep learning for assessment of left ventricular ejection fraction from echocardiographic images","volume":"33","author":"Kusunose K","year":"2020","unstructured":"Kusunose K, Haga A, Yamaguchi N, et al.. Deep learning for assessment of left ventricular ejection fraction from echocardiographic images. J Am Soc Echocardiogr. 2020, 33:632-5.e1. 10.1016\/j.echo.2020.01.009","journal-title":"J Am Soc Echocardiogr"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002287","article-title":"Artificial intelligence-assisted interpretation of systolic function by echocardiogram","volume":"10","author":"Yamaguchi N","year":"2023","unstructured":"Yamaguchi N, Kosaka Y, Haga A, Sata M, Kusunose K. Artificial intelligence-assisted interpretation of systolic function by echocardiogram. Open Heart. 2023, 10:e002287. 10.1136\/openhrt-2023-002287","journal-title":"Open Heart"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0240-2","article-title":"Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram","volume":"25","author":"Attia ZI","year":"2019","unstructured":"Attia ZI, Kapa S, Lopez-Jimenez F, et al.. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019, 25:70-4. 10.1038\/s41591-018-0240-2","journal-title":"Nat Med"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2018.0446","article-title":"Development and validation of deep-learning algorithm for electrocardiography-based heart failure identification","volume":"49","author":"Kwon JM","year":"2019","unstructured":"Kwon JM, Kim KH, Jeon KH, et al.. Development and validation of deep-learning algorithm for electrocardiography-based heart failure identification. Korean Circ J. 2019, 49:629-39. 10.4070\/kcj.2018.0446","journal-title":"Korean Circ J"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1093\/ehjdh\/ztaa015","article-title":"Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features","volume":"2","author":"Kwon JM","year":"2021","unstructured":"Kwon JM, Kim KH, Eisen HJ, et al.. Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features. Eur Heart J Digit Health. 2021, 2:106-16. 10.1093\/ehjdh\/ztaa015","journal-title":"Eur Heart J Digit Health"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0221-y","article-title":"An overview of clinical decision support systems: benefits, risks, and strategies for success","volume":"3","author":"Sutton RT","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020, 3:17. 10.1038\/s41746-020-0221-y","journal-title":"NPJ Digit Med"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0261-3","article-title":"Artificial intelligence for the diagnosis of heart failure","volume":"3","author":"Choi DJ","year":"2020","unstructured":"Choi DJ, Park JJ, Ali T, Lee S. Artificial intelligence for the diagnosis of heart failure. NPJ Digit Med. 2020, 3:54. 10.1038\/s41746-020-0261-3","journal-title":"NPJ Digit Med"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.862095","article-title":"Erroneous data: the Achilles' heel of AI and personalized medicine","volume":"4","author":"Kristiansen TB","year":"2022","unstructured":"Kristiansen TB, Kristensen K, Uffelmann J, Brandslund I. Erroneous data: the Achilles' heel of AI and personalized medicine. Front Digit Health. 2022, 4:862095. 10.3389\/fdgth.2022.862095","journal-title":"Front Digit Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275421-diagnostic-modalities-in-heart-failure-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:06:05Z","timestamp":1724292365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275421-diagnostic-modalities-in-heart-failure-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":170,"URL":"https:\/\/doi.org\/10.7759\/cureus.67432","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}